Next Article in Journal
Cytokine Expression Patterns and Single Nucleotide Polymorphisms (SNPs) in Patients with Chronic Borreliosis
Previous Article in Journal
Actinomycetes: The Antibiotics Producers
Open AccessReview

Antibiotic-Resistant Septicemia in Pediatric Oncology Patients Associated with Post-Therapeutic Neutropenic Fever

1
Departamento de Microbiología del Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Campus Norte, Cuidad de México 52786, Mexico
2
Coordinación Ciclos Clínicos, Facultad de Ciencias de la Salud, Universidad Anáhuac México Campus Norte, Cuidad de México 52786, Mexico
3
Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico
4
Director Facultad de Ciencias de la Salud, Universidad Anáhuac México, Cuidad de México 52786, Mexico
5
Laboratorio de Medicina Genómica, Hospital Regional “Primero de Octubre”, ISSSTE, Av. Instituto Politécnico Nacional 1669, Lindavista, Gustavo A. Madero, Ciudad de Mexico 07300, Mexico
*
Author to whom correspondence should be addressed.
Antibiotics 2019, 8(3), 106; https://doi.org/10.3390/antibiotics8030106
Received: 18 June 2019 / Revised: 15 July 2019 / Accepted: 17 July 2019 / Published: 30 July 2019
Death in cancer patients can be caused by the progression of tumors, their malignity, or other associated conditions such as sepsis, which is a multiphasic host response to a pathogen that can be significantly amplified by endogenous factors. Its incidence is continuously rising, which reflects the increasing number of sick patients at a higher risk of infection, especially those that are elderly, pediatric, or immunosuppressed. Sepsis appears to be directly associated with oncological treatment and fatal septic shock. Patients with a cancer diagnosis face a much higher risk of infections after being immunosuppressed by chemotherapy, radiotherapy, or anti-inflammatory therapy, especially caused by non-pathogenic, Gram-negative, and multidrug-resistant pathogens. There is a notorious difference between the incidence and mortality rates related to sepsis in pediatric oncologic patients between developed and developing countries: they are much higher in developing countries, where investment for diagnosis and treatment resources, infrastructure, medical specialists, cancer-related control programs, and post-therapeutic care is insufficient. This situation not only limits but also reduces the life expectancy of treated pediatric oncologic patients, and demands higher costs from the healthcare systems. Therefore, efforts must aim to limit the progression of sepsis conditions, applying the most recommended therapeutic regimens as soon as the initial risk factors are clinically evident—or even before they are, as when taking advantage of machine learning prediction systems to analyze data. View Full-Text
Keywords: childhood cancer; septicemia; multidrug-resistant (MDR) bacteria; extensively drug-resistant (XDR) bacteria; pandrug-resistant (PDR) bacteria; post-therapeutic neutropenic fever; Mexico childhood cancer; septicemia; multidrug-resistant (MDR) bacteria; extensively drug-resistant (XDR) bacteria; pandrug-resistant (PDR) bacteria; post-therapeutic neutropenic fever; Mexico
Show Figures

Graphical abstract

MDPI and ACS Style

Vázquez-López, R.; Rivero Rojas, O.; Ibarra Moreno, A.; Urrutia Favila, J.E.; Peña Barreto, A.; Ortega Ortuño, G.L.; Abello Vaamonde, J.A.; Aguilar Velazco, I.A.; Félix Castro, J.M.; Solano-Gálvez, S.G.; Barrientos Fortes, T.; González-Barrios, J.A. Antibiotic-Resistant Septicemia in Pediatric Oncology Patients Associated with Post-Therapeutic Neutropenic Fever. Antibiotics 2019, 8, 106.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop